Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00047060 · ClinicalTrials.gov registry record · Phase 1

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

A Phase 1 study of Mycosis Fungoides and Sezary Syndrome, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
Phase 1
Development phase
5
Enrollment target
1
Study location

NCT00047060: Completed Phase 1 study of Mycosis Fungoides and Sezary Syndrome, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

NCT00047060 is a Phase 1 study of Mycosis Fungoides and Sezary Syndrome that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 5 participants, below the 163-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00047060, a Phase 1 study of Mycosis Fungoides and Sezary Syndrome, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

This study will investigate the safety and effectiveness of a modified donor stem cell transplantation procedure for treating advanced mycosis fungoides (MF), a lymphoma primarily affecting the skin, and Sezary syndrome (SS), a leukemic form of the disease. Donated stem cells (cells produced by the bone marrow that mature into the different blood components white cells, red cells and platelets) can cure patients with certain leukemias and lymphomas and multiple myeloma. These cells generate a completely new, functioning bone marrow. In addition, immune cells from the donor grow and generate a new immune system to help fight infections. The new immune cells also attack any residual tumor cells left in the body after intensive chemotherapy. However, stem cell transplantation carries a significant risk of death, because it requires completely suppressing the immune system with high-dose chemotherapy and radiation. In addition, lymphocytes from the donor may cause what is called graft vs. host disease (GvHD), in which these cells see the patient s cells as foreign and mount an immune response to destroy them. To try to reduce these risks, patients in this study will be given low-dose chemotherapy and no radiation, a regimen that is easier for the body to tolerate and involves a shorter period of complete immune suppression. In addition, a monoclonal antibody called Campath-1H will be given to target lymphocytes, including those that have become cancerous. Patients with advanced MF or SS who are between 18 and 70 years of age and have a matched family donor 18 years of age or older may be eligible for this study. Candidates will have a medical history, physical examination and blood tests, lung and heart function tests, X-rays of the chest, eye examination, and bone marrow sampling (withdrawal through a needle of about a tablespoon of marrow from the hip bone), and small skin biopsy (surgical removal of a piece of tissue for microscopic examination) or needle biopsy of

Primary Outcome

Proportion of subjects achieving a complete response. Complete response (CR) is defined as: disappearance of all signs and symptoms of cutaneous T-cell lymphomas (CTCL) for a period of at least one month.

Conditions Studied

Mycosis Fungoides Sezary Syndrome

Interventions

  • DRUG fludarabine
  • DRUG Campath
  • DRUG cyclosporine
  • OTHER A matched peripheral donor stem cells

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2002-07-30
Est. Completion 2019-01-24
Phase Phase 1
National Heart, Lung, and Blood Institute (NHLBI)

501 total trials

What the finished NCT00047060 record still lists

NCT00047060 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 163-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Mycosis Fungoides appearing as the primary indexed condition, and to 4 interventions - of which fludarabine is the first listed.

NCT00047060 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00047060 about?

NCT00047060 is a clinical study titled "Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome". This study will investigate the safety and effectiveness of a modified donor stem cell transplantation procedure for treating advanced mycosis fungoides (MF), a lymphoma primarily affecting the skin, and Sezary syndrome (SS), a leukemic form of the disease. Donated stem cells (cells produced by the ...

What is the current status of trial NCT00047060?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2002-07-30. Estimated completion is 2019-01-24.

What conditions does trial NCT00047060 study?

This clinical trial studies the following conditions: Mycosis Fungoides, Sezary Syndrome.

What interventions are being tested in trial NCT00047060?

The interventions under investigation include: fludarabine (DRUG), Campath (DRUG), cyclosporine (DRUG), A matched peripheral donor stem cells (OTHER).

Who is sponsoring clinical trial NCT00047060?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00047060 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mycosis Fungoides

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00047060's enrollment target sits among peer trials

5 20th of 19 the lowest of 19 other Mycosis Fungoides trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mycosis Fungoides trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00047060, the US trial registry maintained by the National Library of Medicine. NCT00047060 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.